https://orcid.org/0000-0003-0774-3942
References
- Yang IA, Clarke MS, Sim EHA, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.
- Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review. Am J Respir Crit Care Med. 2021;203:689–698. DOI:10.1164/rccm.202005-1854OC
- Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. DOI:10.1056/NEJMoa063070
- Vestbo J, Anderson JA, Brook RD, SUMMIT Investigators, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. DOI:10.1016/S0140-6736(16)30069-1
- Wedzicha JA, Calverley PMA, Seemungal TA, INSPIRE Investigators, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. DOI:10.1164/rccm.200707-973OC
- Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. DOI:10.1056/NEJMoa1516385
- Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. DOI:10.1056/NEJMoa1713901
- Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. DOI:10.1056/NEJMoa1916046
- Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:1508–1516. DOI:10.1164/rccm.201911-2207OC
- Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203:553–564. DOI:10.1164/rccm.202006-2618OC
- Suissa S, Dell’Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD. 2021;1–9. DOI:10.1080/15412555.2021.1977789
- Wedzicha JA, Banerji D, Kostikas K. Single-Inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018;591.
- Schumann DM, Tamm M, Kostikas K, et al. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest. 2019;156:456–465. DOI:10.1016/j.chest.2019.04.012
- van Dijk M, Gan CT, David Koster T, et al. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Res. 2020;6(3):00322–2019. DOI:10.1183/23120541.00322-2019
- Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:324–330. DOI:10.1164/rccm.201605-1014OC
- Almagro P, Salvadó M, Garcia-Vidal C, et al. Recent improvement in long-term survival after a COPD hospitalisation. Thorax. 2010;65:298–302. DOI:10.1136/thx.2009.124818
- Stolz D, Miravitlles M. The right treatment for the right patient with COPD: lessons from the IMPACT trial. Eur. Respir. J. 2020;55(5):200881. DOI:10.1183/13993003.00881-2020